23Jan/13

Transgene inks licensing pact with Portugal's Atral Cipan – Hindu Business Line

January 23, 2013Immunosuppressive Drugsadmin

Transgene inks licensing pact with Portugal’s Atral Cipan
Hindu Business Line
Biotechnology company Transgene Biotek today said it has entered into a licensing and technology transfer agreement with Portugal-based Atral Cipan for its immunosuppressive drug Tacrolimus. As a result of this agreement, Atral Cipan will move the …
Transgene Biotek inks pact with Atral CipanBusiness Standard
Transgene Signs Licensing And Technology Transfer Pact With Atral CipanRTT News

all 4 news articles »

22Jan/13

New Phase 2 Asthma Clinical Trial Now Enrolling at Achieve Clinical Research … – DigitalJournal.com (press release)

January 22, 2013Immunosuppressive Drugsadmin

New Phase 2 Asthma Clinical Trial Now Enrolling at Achieve Clinical Research …DigitalJournal.com (press release)To evaluate the effect of a new asthma drug on lung function in subjects with asthma inadequately controlled by corticosteroids as measure…

21Jan/13

Vaccine may prevent shingles outbreak – Daytona Beach News-Journal

January 21, 2013Immunosuppressive Drugsadmin

Vaccine may prevent shingles outbreakDaytona Beach News-Journal… agents should not receive the vaccine. However, individuals receiving low dose prednisone (less than 20 mg) or methotrexate and azathioprine at doses used for rheumatic disease may safe…

17Jan/13

Combo may be best rescue therapy for resistant Kawasaki disease – Skin and Allergy News Digital Network

January 17, 2013Immunosuppressive Drugsadmin

Combo may be best rescue therapy for resistant Kawasaki disease
Skin and Allergy News Digital Network
The combination of intravenous immunoglobulin, aspirin, and prednisolone appears to be the most effective form of rescue therapy for patients with acute Kawasaki disease who don’t respond to initial IVIG plus aspirin, according to a large Japanese …

and more »

16Jan/13

Everolimus Reduces Size of Noncancerous Kidney Tumors – Cancer Network

January 16, 2013Immunosuppressive Drugsadmin

Everolimus Reduces Size of Noncancerous Kidney TumorsCancer NetworkThe mTOR inhibitor everolimus (Afinitor) has been found to significantly reduce the size of angiomyolipomas, the slow-growing benign tumors commonly associated with tuberous sclerosis c…

16Jan/13

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver … – News-Medical.net

January 16, 2013Immunosuppressive Drugsadmin

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver …
News-Medical.net
The QMS® Everolimus Assay Kit rounds out Thermo Fisher Scientific’s menu of immunoassays for immunosuppressant drugs including cyclosporine, tacrolimus, and mycophenolic acid. Thermo Fisher Scientific has a proven track record for supplying …

and more »

16Jan/13

Thermo Fisher introduces CE marked QMS Everolimus assay kit in EU to help … – pharmabiz.com

January 16, 2013Immunosuppressive Drugsadmin

Thermo Fisher introduces CE marked QMS Everolimus assay kit in EU to help …
pharmabiz.com
The QMS Everolimus Assay Kit rounds out Thermo Fisher Scientific’s menu of immunoassays for immunosuppressant drugs including cyclosporine, tacrolimus, and mycophenolic acid. Thermo Fisher Scientific has a proven track record for supplying …

and more »

15Jan/13

How to Maximize the Potential of mTOR Inhibitors in Breast Cancer—More … – Cancer Network

January 15, 2013Immunosuppressive Drugsadmin

How to Maximize the Potential of mTOR Inhibitors in Breast Cancer—More …
Cancer Network
In this issue of ONCOLOGY, Shaveta Vinayak and Robert Carlson thoroughly summarize the preclinical and clinical studies of mTOR inhibitors, by breast cancer subtype, in both the metastatic and the adjuvant or neoadjuvant setting. Current clinical …

and more »

15Jan/13

mTOR Inhibitors in the Treatment of Breast Cancer – Cancer Network

January 15, 2013Immunosuppressive Drugsadmin

mTOR Inhibitors in the Treatment of Breast CancerCancer NetworkHowever, two independent trials have recently shown that combination everolimus (Afinitor) and tamoxifen or combination everolimus and exemestane (Aromasin) is more effective than either en…

12Jan/13

Phase III data shows Novartis drug Afinitor benefits in non-cancerous tumours … – pharmabiz.com

January 12, 2013Immunosuppressive Drugsadmin

Phase III data shows Novartis drug Afinitor benefits in non-cancerous tumours …pharmabiz.comNovartis announced that the data published in The Lancet shows that patients on Afinitor (everolimus) tablets with non-cancerous kidney tumours known as renal…

Category Archives: Immunosuppressive Drugs